Literature DB >> 20109028

DNA vaccines: a rational design against parasitic diseases.

Joana A Carvalho1, Jean Rodgers, Jorge Atouguia, Duarte M F Prazeres, Gabriel A Monteiro.   

Abstract

Parasitic diseases are one of the most devastating causes of morbidity and mortality worldwide. Although immunization against these infections would be an ideal solution, the development of effective vaccines has been hampered by specific challenges posed by parasitic pathogens. Plasmid-based DNA vaccines may prove to be promising immunization tools in this area because vectors can be designed to integrate several antigens from different stages of the parasite life cycle or different subspecies; vaccines, formulations and immunization protocols can be tuned to match the immune response that offers protective immunity; and DNA vaccination is an affordable platform for developing countries. Partial and full protective immunity have been reported following DNA vaccination against the most significant parasitic diseases in the world.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20109028     DOI: 10.1586/erv.09.158

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  9 in total

Review 1.  Micro- and nanoparticulates for DNA vaccine delivery.

Authors:  Eric Farris; Deborah M Brown; Amanda E Ramer-Tait; Angela K Pannier
Journal:  Exp Biol Med (Maywood)       Date:  2016-04-04

2.  Stable antigen is most effective for eliciting CD8+ T-cell responses after DNA vaccination and infection with recombinant vaccinia virus in vivo.

Authors:  Christopher Schliehe; Annegret Bitzer; Maries van den Broek; Marcus Groettrup
Journal:  J Virol       Date:  2012-07-03       Impact factor: 5.103

3.  Approaches towards DNA vaccination against a skin ciliate parasite in fish.

Authors:  Louise von Gersdorff Jørgensen; Jens Sigh; Per Walter Kania; Lars Holten-Andersen; Kurt Buchmann; Theodore Clark; Jesper Skou Rasmussen; Katja Einer-Jensen; Niels Lorenzen
Journal:  PLoS One       Date:  2012-11-07       Impact factor: 3.240

4.  C-terminal domain deletion enhances the protective activity of cpa/cpb loaded solid lipid nanoparticles against Leishmania major in BALB/c mice.

Authors:  Delaram Doroud; Farnaz Zahedifard; Alireza Vatanara; Yasaman Taslimi; Rouholah Vahabpour; Fatemeh Torkashvand; Behrooz Vaziri; Abdolhossein Rouholamini Najafabadi; Sima Rafati
Journal:  PLoS Negl Trop Dis       Date:  2011-07-12

5.  Preclinical safety and tolerability of a repeatedly administered human leishmaniasis DNA vaccine.

Authors:  O Riede; K Seifert; D Oswald; A Endmann; C Hock; A Winkler; F J Salguero; M Schroff; S L Croft; C Juhls
Journal:  Gene Ther       Date:  2015-04-30       Impact factor: 5.250

6.  Anticipation of Antigenic Sites for the Goal of Vaccine Designing Against Nipah Virus: An Immunoinformatics Inquisitive Quest.

Authors:  Suraj Kumar Sharma; Shivani Srivastava; Ajay Kumar; Vivek Srivastava
Journal:  Int J Pept Res Ther       Date:  2021-05-11       Impact factor: 1.931

7.  Risk Factors of Noncompliance to Preventive Mass Drug Administration for Eliminating Lymphatic Filariasis: A Case-Control Study in Jawi District, Northwest Ethiopia.

Authors:  Fetene Mihretu; Gebeyehu Tsega; Melesse Belayneh; Mesafint Molla Adane
Journal:  J Trop Med       Date:  2022-09-21

8.  Construction and In vitro Expression Analyses of a DNA Plasmid Encoding Dense Granule GRA5 Antigen of Toxoplasma gondii.

Authors:  Jalal Babaie; Ghazaleh Sadeghiani; Majid Golkar
Journal:  Avicenna J Med Biotechnol       Date:  2011-07

9.  Combined immunization using DNA-Sm14 and DNA-Hsp65 increases CD8+ memory T cells, reduces chronic pathology and decreases egg viability during Schistosoma mansoni infection.

Authors:  Milena Sobral Espíndola; Fabiani Gai Frantz; Luana Silva Soares; Ana Paula Masson; Cristiane Tefé-Silva; Claudia Silva Bitencourt; Sérgio Costa Oliveira; Vanderlei Rodrigues; Simone Gusmão Ramos; Célio Lopes Silva; Lúcia Helena Faccioli
Journal:  BMC Infect Dis       Date:  2014-05-16       Impact factor: 3.090

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.